Mood destabilizers?: A review of mood stabilizer-associated mania
Pharmacopsychiatry · 25.08.2026
DOI: 10.1055/a-2934-0429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 25.08.2026. Verfasst von Shaina E Schwartz und 3 weiteren Autor:innen. Beteiligte Einrichtung: High Point University Fred Wilson School of Pharmacy, Clinical Sciences, North Carolina, United States, High Point. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Mania is associated with significant morbidity and mortality. Mood stabilizing medications are typically used to prevent manic episodes, yet in some cases can precipitate them. The literature on this rare but potentially serious paradoxical reaction is lacking. A structured literature review was performed to identify case reports of adults experiencing manic symptoms associated with the routine use of medications with mood stabilizing properties (i.e., valproate, lithium, carbamazepine, lamotrigine, oxcarbazepine, and topiramate). A total of eight articles describing 12 unique patients were included in the analysis. The majority of patients (58%) had a previous diagnosis of bipolar spectrum disorder. The most frequent offending agent was lamotrigine (58%), followed by topiramate (33%), and carbamazepine (8%). Most patients (92%) were taking concomitant medications, mainly antipsychotics (50%) and other mood stabilizers (50%). The mean time between treatment initiation or dose escalation of the mood stabilizer and the onset of mania was 7 days. In all but two cases, the mood stabilizer was discontinued upon presentation. Improvement in symptoms was observed within a mean of 9 days following intervention. Mood stabilizer-associated mania appears to be relatively acute in onset and can be reversed by discontinuation. It commonly, but not exclusively, occurs in patients with a history of bipolar spectrum disorder who are already prescribed medications with mood stabilizing properties. In cases of new onset or worsening mania following the initiation or dose escalation of a mood stabilizer (especially lamotrigine and topiramate), this paradoxical reaction should be considered.
Autor:innen und Institutionen
- High Point University Fred Wilson School of Pharmacy, Clinical Sciences, North Carolina, United States, High Point.
ORCID-Profile: Shaina E Schwartz
Zitieren
APA
Schwartz, S. E., Hundley, A. M., Chan, C. Y. M., & Baalmann, A. R. (2026). Mood destabilizers?: A review of mood stabilizer-associated mania. Pharmacopsychiatry. https://doi.org/10.1055/a-2934-0429
Vancouver
Schwartz SE, Hundley AM, Chan CYM, Baalmann AR. Mood destabilizers?: A review of mood stabilizer-associated mania. Pharmacopsychiatry. 2026. doi:10.1055/a-2934-0429
BibTeX
@article{Schwartz2026,
author = {Schwartz, Shaina E and Hundley, Allyson M and Chan, Chak Yui M and Baalmann, Angela R},
title = {Mood destabilizers?: A review of mood stabilizer-associated mania},
journal = {Pharmacopsychiatry},
year = {2026},
doi = {10.1055/a-2934-0429}
}
EUVIMED